Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma
Abstract. The serum soluble CD163 (sCD163) is elevated in patients with inflammatory disease and several types of cancer. However, the prognostic value of serum sCD163 in pancreatic ductal adenocarcinoma (PDAC) has not yet been investigated. In this study, serum level of sCD163 was measured by using...
Những tác giả chính: | Qinglin Fei, MD, Yu Pan, MD, PhD, Xingxing Yu, MD, Ronggui Lin, MD, PhD, Xianchao Lin, MD, PhD, Heguagn Huang, MD |
---|---|
Định dạng: | Bài viết |
Ngôn ngữ: | English |
Được phát hành: |
Wolters Kluwer Health/LWW
2020-09-01
|
Loạt: | Journal of Pancreatology |
Truy cập trực tuyến: | http://journals.lww.com/10.1097/JP9.0000000000000055 |
Những quyển sách tương tự
-
Predictors of occult metastases in potentially Resectable pancreatic ductal adenocarcinoma
Bằng: Takeshi Murakami, MD, et al.
Được phát hành: (2024-08-01) -
Preoperative Biliary Drainage Does Not Independently Reduce Survival After Pancreaticoduodenectomy Among Patients With Pancreatic Ductal Adenocarcinoma
Bằng: Karin Johansen, MD, et al.
Được phát hành: (2021-09-01) -
Surgical Resection or Ablation for Recurrent Pancreatic Ductal Adenocarcinoma
Bằng: Boram Lee, MD, et al.
Được phát hành: (2021-09-01) -
Pancreatic ductal adenocarcinoma: the role of circulating tumor DNA
Bằng: Joseph R. Habib, MD, et al.
Được phát hành: (2019-09-01) -
Long-Term Outcomes of Venous Resections in Pancreatic Ductal Adenocarcinoma Patients
Bằng: Martin Sillesen, MD, PhD, et al.
Được phát hành: (2022-12-01)